ArticleeLife2024
Associations of combined phenotypic aging and genetic risk with incident cancer: A prospective cohort study.
Article in eLife, 2024. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 27 papers.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
27 citing papers in PubMed, 10 citations in OpenAlex.
- Liver-specific phenotypic aging, behavior and genetic risks, and long-term liver-related outcomes.GeroScience · 2026Article
- Biological aging, circulating lipid biomarkers and pancreatic diseases: a prospective cohort study based on the UK Biobank.The journal of nutrition, health & aging · 2026Article
- Accelerated Biological Aging Increases the Risk of Head and Neck Cancer: Insights From Genetic Instruments of Epigenetic Clocks.Molecular carcinogenesis · 2026Article
- Phenotypic age acceleration and genetic risk synergistically increase age-related eye disease risk in the UK Biobank.Scientific reports · 2026Article
- Biological age acceleration predicts mortality and heart failure after acute myocardial infarction in older adults.Journal of geriatric cardiology : JGC · 2026Article
- Association of accelerated phenotypic aging, lifestyle and genetic risk with progression of cardiometabolic multimorbidity: a multi-state model analysis.GeroScience · 2026Article
- Phenotypic age acceleration as a novel predictor of benign prostatic hyperplasia: a prospective cohort study.GeroScience · 2026Article
- Phenotypic age acceleration: a novel biomarker associated with increased risk of metabolic dysfunction-associated fatty liver disease.Nutrition & metabolism · 2026Article
- The association between the planetary health diet index (PHDI) and muscular dystrophies: A mediating role of phenotypic age.Medicine · 2026Article
- Genetic insights into socioeconomic inequalities and adiposity-related interventions for reducing accelerated biological aging.International journal of obesity (2005) · 2026Observational
- Aging and increased cancer risk: exploring the potential of LE8 score to mitigate risk.npj aging · 2026Article
- Phenotypic age acceleration and early-onset lung cancer: a case-control and prognostic cohort study involving multiple clinical centres with validation in the UK Biobank.EBioMedicine · 2026Article
- A prospective study of age-related functional impairments, mortality, and life expectancy of Chinese adults aged 50.Communications medicine · 2026Article
- PhenoAge and PhenoAgeAccel do not outperform chronological age in predicting physical performance decline or mortality in community-dwelling older adults.The journals of gerontology. Series A, Biological sciences and medical sciences · 2026Article
- Targeted therapies in lung cancer: personalizing treatment across the age spectrum.Frontiers in oncology · 2026Review
- Article
- Article
- Combined association between phenotypic age acceleration and dietary fiber intake with mortality in middle-aged and elderly cancer survivors.Nutrition journal · 2025Article
- Association of estimated glucose disposition rate with aging acceleration and mortality risk in individuals with cardiovascular-kidney-metabolic syndrome: evidence from two large national population-based studies.Cardiovascular diabetology · 2025Article
- Profile of biological aging in first primary cancers: a pan-cancer analysis of two large-scale cohorts from the UK and Hong Kong.BMC medicine · 2025Article
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
13 authors at 4 institutions in 4 countries.
Funding
Abstract
Background: Age is the most important risk factor for cancer, but aging rates are heterogeneous across individuals. We explored a new measure of aging-Phenotypic Age (PhenoAge)-in the risk prediction of site-specific and overall cancer. Methods: Using Cox regression models, we examined the association of Phenotypic Age Acceleration (PhenoAgeAccel) with cancer incidence by genetic risk group among 374,463 participants from the UK Biobank. We generated PhenoAge using chronological age and nine biomarkers, PhenoAgeAccel after subtracting the effect of chronological age by regression residual, and an incidence-weighted overall cancer polygenic risk score (CPRS) based on 20 cancer site-specific polygenic risk scores (PRSs). Results: Compared with biologically younger participants, those older had a significantly higher risk of overall cancer, with hazard ratios (HRs) of 1.22 (95% confidence interval, 1.18-1.27) in men, and 1.26 (1.22-1.31) in women, respectively. A joint effect of genetic risk and PhenoAgeAccel was observed on overall cancer risk, with HRs of 2.29 (2.10-2.51) for men and 1.94 (1.78-2.11) for women with high genetic risk and older PhenoAge compared with those with low genetic risk and younger PhenoAge. PhenoAgeAccel was negatively associated with the number of healthy lifestyle factors (Beta = -1.01 in men, p<0.001; Beta = -0.98 in women, p<0.001). Conclusions: Within and across genetic risk groups, older PhenoAge was consistently related to an increased risk of incident cancer with adjustment for chronological age and the aging process could be retarded by adherence to a healthy lifestyle. Funding: This work was supported by the National Natural Science Foundation of China (82230110, 82125033, 82388102 to GJ; 82273714 to MZ); and the Excellent Youth Foundation of Jiangsu Province (BK20220100 to MZ).
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.